Home
Site Map
Contact Us
Graphics Version
Printer Version
Main Navigation
ABOUT US
COMPANY PROFILE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
STRATEGY
Recent
2007
2006
2005
2004
2003
2002
2001
2000
MANAGEMENT TEAM
Recent
2007
2006
2005
2004
2003
2002
2001
2000
BOARD OF DIRECTORS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SCIENTIFIC ADVISORY BOARD
Recent
2007
2006
2005
2004
2003
2002
2001
2000
CONTACT US
Recent
2007
2006
2005
2004
2003
2002
2001
2000
THERAPEUTIC FOCUS
CNS
Huntington's Disease
Myasthenia Gravis
Parkinson's Disease
Epilepsy
CARDIOVASCULAR
Recent
2007
2006
2005
2004
2003
2002
2001
2000
PRODUCTS
PIPELINE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
MIRAXION (AMR101)
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 / Derivatives
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EN101
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SUBLINGUAL APOMORPHINE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AMR101 / AMR109
Recent
2007
2006
2005
2004
2003
2002
2001
2000
NASAL LORAZEPAM
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AMR103
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SCIENCE & TECHNOLOGY
INTRODUCTION
Lipophilic Platform
Targeted Lipid Transport Technology Platform
Cholinergic Platform
PARTNERING
PARTNERING
Recent
2007
2006
2005
2004
2003
2002
2001
2000
STRATEGIC ALLIANCES
Recent
2007
2006
2005
2004
2003
2002
2001
2000
BUSINESS DEVELOPMENT
Recent
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
Recent
2007
2006
2005
2004
2003
2002
2001
2000
STOCK INFORMATION
Recent
2007
2006
2005
2004
2003
2002
2001
2000
CORPORATE GOVERNANCE
AUDIT COMMITTEE
REMUNERATION COMMITTEE
LEAD INDEPENDENT DIRECTOR
CODE OF ETHICS
MEMORANDUM AND ARTICLES OF ASSOCIATION
PRESENTATIONS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
PRESS RELEASES
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
FINANCIAL REPORTS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
SEC FILINGS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
RULE 26 INFORMATION
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EGM 2008
Recent
2007
2006
2005
2004
2003
2002
2001
2000
AGM 2007
Recent
2007
2006
2005
2004
2003
2002
2001
2000
ANALYST COVERAGE
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EMAIL ALERTS
Recent
2007
2006
2005
2004
2003
2002
2001
2000
REQUEST INFORMATION
Recent
2007
2006
2005
2004
2003
2002
2001
2000
INVESTOR RELATIONS
OVERVIEW
STOCK INFORMATION
CORPORATE GOVERNANCE
PRESENTATIONS
PRESS RELEASES
Recent
2007
2006
2005
2004
2003
2002
2001
2000
EVENTS
FINANCIAL REPORTS
SEC FILINGS
RULE 26 INFORMATION
EGM 2008
AGM 2007
ANALYST COVERAGE
EMAIL ALERTS
REQUEST INFORMATION
Mailing List
Join our mailing list if you wish to receive updates by email
Mailing List
Unsubscribe »
INVESTOR
RELATIONS
PRESS RELEASES
11-Dec-2000
AMARIN ANNOUNCES INITIATION OF PHASE III STUDY OF LAX-101 FOR THE TREATMENT OF HUNTINGTON'S DISEASE
28-Nov-2000
AMARIN CORPORATION TO PRESENT AT S.G. COWEN GLOBAL HEALTHCARE CONFERENCE
27-Nov-2000
AMARIN LICENSES U.S. RIGHTS TO LAX-101 FOR THE TREATMENT OF HUNTINGTON'S DISEASE FROM LAXDALE LTD.
9-Nov-2000
FISCAL 2000 3RD QUARTER RESULTS
6-Oct-2000
AMARIN CORPORATION FILES REGISTRATION STATEMENT ON FORM F-3
1-Sep-2000
FISCAL 2000 2ND QUARTER RESULTS
26-Jun-2000
$11.5M EQUITY PRIVATE PLACEMENT
26-Jun-2000
FISCAL 2000 1ST QUARTER RESULTS
10-May-2000
PRELIMINARY RESULTS FOR 16 MONTHS ENDED 31 DECEMBER 1999
10-May-2000
AMARIN ACQUIRES BRANDED PHARMACEUTICAL PRODUCT PORTFOLIO
Website Design and Development by Webtrade.ie